X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3654) 3654
Publication (211) 211
Book Review (53) 53
Magazine Article (18) 18
Book Chapter (12) 12
Newsletter (8) 8
Conference Proceeding (4) 4
Book / eBook (3) 3
Dissertation (2) 2
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3235) 3235
anticoagulants - therapeutic use (2018) 2018
enoxaparin (1935) 1935
enoxaparin - therapeutic use (1818) 1818
female (1769) 1769
male (1607) 1607
index medicus (1459) 1459
middle aged (1190) 1190
aged (1126) 1126
molecular-weight heparin (847) 847
prevention (832) 832
venous thromboembolism (814) 814
adult (808) 808
treatment outcome (770) 770
anticoagulants (722) 722
hematology (665) 665
anticoagulants - adverse effects (664) 664
unfractionated heparin (664) 664
heparin, low-molecular-weight - therapeutic use (642) 642
thromboembolism (618) 618
fibrinolytic agents - therapeutic use (588) 588
anticoagulants - administration & dosage (572) 572
peripheral vascular disease (567) 567
risk factors (561) 561
enoxaparin - administration & dosage (541) 541
enoxaparin - adverse effects (531) 531
heparin (529) 529
deep-vein thrombosis (527) 527
heparin - therapeutic use (522) 522
surgery (507) 507
thrombosis (483) 483
venous thromboembolism - prevention & control (473) 473
cardiac & cardiovascular systems (454) 454
venous thrombosis - prevention & control (453) 453
pharmacology & pharmacy (439) 439
thromboprophylaxis (420) 420
medicine, general & internal (417) 417
aged, 80 and over (414) 414
drug therapy (410) 410
prophylaxis (391) 391
hemorrhage - chemically induced (388) 388
thromboembolism - prevention & control (352) 352
retrospective studies (351) 351
postoperative complications - prevention & control (343) 343
prospective studies (337) 337
rivaroxaban (324) 324
warfarin (304) 304
therapy (278) 278
randomized controlled trials as topic (275) 275
warfarin - therapeutic use (275) 275
risk (274) 274
anticoagulation (268) 268
time factors (266) 266
myocardial infarction - drug therapy (263) 263
pregnancy (260) 260
venous thrombosis (256) 256
pulmonary-embolism (253) 253
venous thrombosis - drug therapy (253) 253
abridged index medicus (250) 250
factor xa inhibitors (248) 248
management (245) 245
medicine & public health (243) 243
trial (240) 240
safety (238) 238
acute coronary syndromes (237) 237
care and treatment (233) 233
double-blind (233) 233
drug therapy, combination (223) 223
pulmonary embolism (219) 219
aspirin (217) 217
polysaccharides - therapeutic use (217) 217
low-molecular-weight heparin (216) 216
pulmonary embolism - prevention & control (215) 215
health aspects (214) 214
venous thromboembolism - etiology (211) 211
risk assessment (203) 203
fondaparinux (201) 201
heparin - adverse effects (200) 200
double-blind method (198) 198
venous thrombosis - etiology (198) 198
animals (196) 196
anticoagulants - pharmacology (196) 196
dose-response relationship, drug (196) 196
platelet aggregation inhibitors - therapeutic use (195) 195
acute disease (192) 192
low molecular weight heparin (192) 192
adolescent (191) 191
unstable angina (190) 190
follow-up studies (189) 189
dosage and administration (188) 188
administration, oral (186) 186
mortality (186) 186
analysis (185) 185
research (184) 184
metaanalysis (183) 183
aspirin - therapeutic use (178) 178
heparin, low-molecular-weight - adverse effects (177) 177
enoxaparin - pharmacology (176) 176
thrombosis - prevention & control (176) 176
drug administration schedule (175) 175
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3456) 3456
Spanish (52) 52
German (51) 51
French (46) 46
Russian (40) 40
Polish (10) 10
Italian (8) 8
Chinese (6) 6
Portuguese (6) 6
Czech (3) 3
Serbian (3) 3
Ukrainian (3) 3
Finnish (2) 2
Norwegian (2) 2
Arabic (1) 1
Bulgarian (1) 1
Japanese (1) 1
Korean (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Circulation, ISSN 0009-7322, 07/2007, Volume 116, Issue 5, pp. 552 - 560
fondaparinux | CARDIAC & CARDIOVASCULAR SYSTEMS | bivalirudin | STROKE PREVENTION | myocardial infarction | INITIAL TREATMENT | heparin | ST-ELEVATION | PERCUTANEOUS CORONARY INTERVENTION | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | anticoagulants | mortality | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | enoxaparin | NONVALVULAR ATRIAL-FIBRILLATION | Fibrinolytic Agents - classification | Recombinant Proteins - therapeutic use | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Benzylamines - adverse effects | Factor Xa Inhibitors | Anticoagulants - classification | Humans | Thrombin - antagonists & inhibitors | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Rivaroxaban | Pyridines - adverse effects | Angina, Unstable - drug therapy | Prothrombin - antagonists & inhibitors | Hirudins - pharmacokinetics | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Polysaccharides - therapeutic use | Azetidines - adverse effects | Peptide Fragments - pharmacokinetics | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Forecasting | Azetidines - therapeutic use | Brain Ischemia - drug therapy | Peptide Fragments - therapeutic use | Benzylamines - pharmacokinetics | Hemorrhage - chemically induced | Heparin - therapeutic use | Recombinant Proteins - pharmacokinetics | Dabigatran | Fibrinolytic Agents - pharmacokinetics | Fibrinolytic Agents - therapeutic use | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Thrombophilia - drug therapy | Pyridines - therapeutic use | Azetidines - pharmacokinetics | Clinical Trials as Topic | Coumarins - therapeutic use | Polysaccharides - pharmacology | Thiophenes - pharmacokinetics | Myocardial Infarction - drug therapy | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Benzylamines - therapeutic use | Physiological aspects | Usage | Warfarin | Heparin
Journal Article
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Laporte, Silvy and Schulman, Sam and Gent, Michael and Turpie, Alexander and Martinelli, Ida and Lensing, Anthonie W and Muhlhofer, Eva and Tewes, Miriam and Trajanovic, Mila and Muller, Karin and Kim, Calvin and Gebel, Martin and Benson, Alice and Pap, Akos Ferenc and Goie, Juliette and Horvat-Broecker, Anea and Spadari, Giovanni and Peters-Wulf, Cornelia and Roig, J and Baker, R and Bianchi, A and Blombery, P and Brighton, T and Campbell, P and Carroll, P and Geraghty, R and Chong, B and Ramanathan, S and Archis, C and Coughlin, P and Salem, H and Crispin, P and Dean, M and Soni, R and Denaro, C and Kubler, P and Coghlan, D and Gallus, A and Gan, T. Eng and Tran, H and Coleman, C and Jackson, D and Khalafallah, A and Leahy, M and Leyden, M and Leyden, D and Sturtz, C and McCann, A and Gibbs, H and McRae, S and Richards, B and ... and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 7, p. CD006650
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
Mortality and morbidity in acute coronary syndromes (ACSs), caused principally by plaque erosion or rupture leading to thrombus formation and myocardial... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2499 - 2510
In this clinical trial, rivaroxaban, an oral factor Xa inhibitor, was effective in the initial and continued treatment of symptomatic venous thromboembolism;... 
MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | THERAPY | DISEASE | PREVENTION | DEEP-VEIN THROMBOSIS | IDRAPARINUX | Thiophenes - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Injections, Subcutaneous | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Acute Disease | Double-Blind Method | Venous Thrombosis - drug therapy | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acenocoumarol - adverse effects | Intention to Treat Analysis | Pulmonary Embolism - drug therapy | Acenocoumarol - therapeutic use | Aged | Hemorrhage - chemically induced | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Health aspects | Risk factors | Anticoagulants | Bone surgery | Veins & arteries | Venous Thrombosis | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Acenocoumarol | Vitamin K | Warfarin | Enoxaparin | Morpholines | Human health and pathology | Pulmonary Embolism | MEDICIN OCH HÄLSOVETENSKAP | Oral | MEDICAL AND HEALTH SCIENCES | Administration | chemically induced | drug therapy | Subcutaneous | antagonists & inhibitors | Injections | adverse effects | therapeutic use
Journal Article